The molecular basis of galactosemia - Past, present and future

Published in:
Gene

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Accepted Manuscript

The molecular basis of galactosemia – past, present and future

David J. Timson

Please cite this article as: Timson, David J., The molecular basis of galactosemia – past, present and future, *Gene* (2015), doi: 10.1016/j.gene.2015.06.077

The molecular basis of galactosemia – past, present and future

David J Timson*, School of Biological Sciences, Queen's University Belfast, Medical Biology Centre,

97 Lisburn Road, Belfast, BT9 7BL. UK.

* Corresponding author. School of Biological Sciences, Queen's University Belfast, Medical Biology

Centre, 97 Lisburn Road, Belfast, BT9 7BL. UK.

Tel: +44(0)28 9097 5875

Fax: +44(0)28 9097 5877

Email: d.timson@qub.ac.uk

Abstract

Galactosemia, an inborn error of galactose metabolism, was first described in the 1900s by von Ruess. The subsequent 100 years have seen considerable progress in understanding the underlying genetics and biochemistry of this condition. Initial studies concentrated on increasing the understanding of the clinical manifestations of the disease. However, Leloir's discovery of the pathway of galactose catabolism in the 1940s and 1950s enabled other scientists, notably Kalckar, to link the disease to a specific enzymatic step in the pathway. Kalckar's work established that defects in galactose 1-phosphate uridylyltransferase (GALT) were responsible for the majority of cases of galactosemia. However, over the next three decades it became clear that there were two other forms of galactosemia: type II resulting from deficiencies in galactokinase (GALK1) and type III where the affected enzyme is UDP-galactose 4'-epimerase (GALE). From the 1970s, molecular biology approaches were applied to galactosemia. The chromosomal locations and DNA sequences of the three genes were determined. These studies enabled modern biochemical studies. Structures of the proteins have been determined and biochemical studies have shown that enzymatic impairment often results from misfolding and consequent protein instability. Cellular and model organism studies have demonstrated that reduced GALT or GALE activity results in increased oxidative stress. Thus, after a century of progress, it is possible to conceive of improved therapies including drugs to manipulate the pathway to reduce potentially toxic intermediates, antioxidants to reduce the oxidative stress of cells or use of "pharmacological chaperones" to stabilise the affected proteins.

Introduction: galactosemia

Galactosemia is a group of three inherited metabolic diseases characterised by the inability to metabolise the aldose monosaccharide galactose (Fridovich-Keil , 2006; Fridovich-Keil & Walter , 2008). This is especially important in young mammals since the main sugar present in milk is lactose, a disaccharide of galactose and glucose. In the most severe forms, the disease manifests as a life-threatening, progressive loss of function of a number of tissues and organs including the ovaries and brain (Waggoner *et al.* , 1990; Schweitzer *et al.* , 1993; Ridel *et al.* , 2005; Rubio-Gozalbo *et al.* , 2010; Fridovich-Keil *et al.* , 2011; Berry , 2012; Waisbren *et al.* , 2012; Karadag *et al.* , 2013; Potter *et al.* , 2013; Timmers *et al.* , 2015). As a consequence it can be associated with significant pathology and cognitive disability in childhood (Bosch , 2006; Timmers *et al.* , 2011). However, these outcomes vary widely and the mildest forms of the diseases are essentially asymptomatic. Currently, the only treatment is the restriction of galactose (and lactose) from the diet (Holton , 1996; Gleason *et al.* , 2000). This treatment is unsatisfactory in many cases, especially in childhood; however, in many countries, it is relaxed in adult patients and this is generally considered to be safe (Van Calcar *et al.* , 2014; Adam *et al.* , 2015). In severe cases of the disease, it tends to slow or reduce the development of symptoms but does not always prevent them (Gitzelmann & Steinmann , 1984; Widhalm *et al.* , 1997).

In the majority of organisms, galactose is mainly metabolised by the Leloir pathway (Figure 1). This short metabolic pathway converts α-D-galactose into glucose 1-phosphate (Frey , 1996). This compound can be isomerised into glucose 6-phosphate by the action of phosphoglucomutase (PGM, EC 5.4.2.2). Thus, galactose is converted into a glycolytic intermediate at the cost of one molecule of ATP per molecule of galactose. Since the first enzyme of the pathway is highly specific for the α-anomer of D-galactose, another enzyme aldose 1-epimerase (GALM; EC 5.1.3.3) catalyses the equilibrium between the α- and β-forms of the sugar (Bailey *et al.* , 1969; Timson & Reece , 2003b;

3

Thoden *et al.* , 2004). Three types of galactosemia are recognised. The most common, type I or

classical galactosemia (OMIM #230400), was the first to be discovered. It has an estimated

incidence of approximately 1/30,000; however it is much higher in some groups most notably Irish

travellers for whom the frequency is 1/480 (Murphy *et al.* , 1999; J. M. Flanagan *et al.* , 2010; Coss *et

al.* , 2013). This disease results from mutations in the gene encoding galactose 1-phosphate

uridylyltransferase (GALT; EC 2.7.7.12) (Leslie *et al.* , 1992; Tyfield *et al.* , 1999; T. J. McCorvie &

Timson , 2011a; T. J. McCorvie & Timson , 2011b). The range of symptoms is wide ranging from

relatively mild to life threatening (Fridovich-Keil & Walter , 2008). In contrast, type II galactosemia

(OMIM#230200) is the mildest form of the disease with only early onset cataracts confirmed as a

consequence of the disease (Bosch *et al.* , 2002). Dietary restriction of galactose often resolves

these cataracts, particularly if the disease is detected early through a screening programme

(Hennermann *et al.* , 2011; Janzen *et al.* , 2011). Type II galactosemia is caused by mutations in the

gene encoding galactokinase (GALK1; EC 2.7.1.6) (Stambolian *et al.* , 1995; Bergsma *et al.* , 1996;

Holden *et al.* , 2004; Timson *et al.* , 2009). Type III galactosemia (OMIM#230250), most likely the

rarest and currently the least studied form of the disease, results from mutations in the gene

encoding UDP-galactose 4'-epimerase (GALE; EC 5.1.3.2) (Timson , 2006). It is still common to see

this disease described as occurring in two forms: a very mild (or "peripheral") form or a severe (or

"generalised") form. This concept was decisively debunked almost a decade ago: like the other two

types of galactosemia, type III is a continuum disease in which the precise manifestations in each

patient are determined by a combination of genotype and environment (Openo *et al.* , 2006).

The discovery of type I galactosemia: from disease to gene

The first recognised report of galactosemia was made by the Austrian ophthalmologist August von

Ruess in 1908 (Von Reuss , 1908). However, the first detailed report was made in 1917 by Friedrich

Göppert (Göppert , 1917). (As an interesting aside, Friedrich Göppert's scientific achievements have

been largely overshadowed by those of his daughter, the Nobel Prize winning physicist Maria

Goeppert-Mayer (Goeppert-Mayer , 1963).) This report of excess galactose in the urine of a patient

recognised that the disease had an inherited element. The child concerned had reduced cognitive

development and it was observed that feeding him cottage cheese, in which the bulk of the lactose

and galactose have been partly metabolised by the bacteria present, reduced the concentration of

galactose in the urine (Göppert , 1917; Shahani & Chandan , 1979). In the first half of the twentieth

century a number of reports of the disease (sometimes misleadingly called "galactose diabetes")

appeared. These established that the disease tends to manifest in early childhood, can be partially

reversed by the removal of galactose from the diet and that the liver is one the main organs affected

(Mason & Turner , 1935; Bruck & Rapoport , 1945; Mellinkoff *et al.* , 1945; Goldbloom & Brickman ,

1946; Greenman & Rathbun , 1948; Bell *et al.* , 1950).

The bulk of these studies were conducted before the metabolic pathway for the catabolism of

galactose was fully elucidated. This discovery of this pathway was almost entirely due to the

pioneering work of the Argentinian biochemist, Louis Leloir who earned the Nobel Prize in 1970 for

this and related work on sugar-nucleotides (Cabib , 1970; L. F. Leloir , 1983). Prior to the elucidation

of the pathway, Leloir and others had investigated the phosphorylation of galactose at the expense

of ATP in a reaction catalysed by galactokinase (Reiner , 1947; Trucco *et al.* , 1948; Spratt , 1949;

Wilkinson , 1949). Leloir's key observation was that galactose is transformed into a glucose

derivative, most likely glucose 6-phosphate, in a reaction with required at least one other enzyme

and a heat-resistant cofactor (Caputto *et al.* , 1949). This overall conversion required a Walden

inversion (i.e. the reversal of stereochemistry at a specific position in the molecule) and the enzyme

was tentatively named galactowaldenase. Subsequent work demonstrated that the cofactor was

UDP-glucose (Caputto *et al.* , 1950; Cardini *et al.* , 1950). This compound is a representative of a

group of sugar derivatives important not only in this pathway, but also in the synthesis of

polysaccharides and the oligosaccharide moieties of glycoproteins and glycolipids. Leloir's critical

role in their discovery is recognised by these compounds sometimes being referred to as "Leloir

5

sugars". The transformation of UDP-glucose into UDP-galactose was shown to be part of the overall

process (L. F. Leloir , 1951; Paladini & Leloir , 1952). It became clear that the enzyme

"galactowaldenase" catalyses two distinct reactions: the epimerisation of the galactose moiety in

UDP-galactose and the transfer of the uridyl group onto galactose 1-phosphate (L. F. Leloir , 1951).

The interconversion of UDP-galactose and UDP-glucose (the step of the Leloir pathway which alters

the sugar stereochemistry) is now known to be catalysed by UDP-galactose 4'epimerase (GALE,

Figure 1) and galactowaldenase was increasingly used to refer to this enzyme. GALE was shown to

require NAD$^+$ (then known as diphosphopyridine nucleotide, DPN) as an essential cofactor (Maxwell ,

1956). The other aspect of the "galactowaldenase" reaction, the transfer of a uridyl group to

galactose 1-phosphate, is catalysed by galactose 1-phosphate uridylyltransferase (GALT, Figure 1).

It was not until 1956 that the genetic nature of the disease was elucidated by Kalckar and co-

workers (Isselbacher *et al.* , 1956). The same research group had already demonstrated that

galactosemic patients lacked GALT and GALE activity and accumulated the intermediate galactose 1-

phosphate (Kalckar Anderson Isselbacher , 1956a; Kalckar Anderson Isselbacher , 1956b). However,

GALE activity could be restored in cell extracts by addition of NAD$^+$ (Isselbacher *et al.* , 1956). On this

basis, it was concluded that galactosemia was a single gene disorder resulting from one or more

mutations in the gene coding for GALT. This work also provided the basis for definitive tests for the

disease – measurement of either galactose 1-phosphate accumulation or lack of GALT activity

(Donnell *et al.* , 1963; W. G. Ng *et al.* , 1964). Since GALT activity was reduced in otherwise

asymptomatic relatives of patients it was concluded that galactosemia is normally a recessive

condition (Hsia *et al.* , 1958; Hugh-Jones *et al.* , 1960).

The human *GALT* gene was assigned to chromosome 3 in 1974, to chromosome 2 in 1975 and to

chromosome 9 in 1978 (Tedesco *et al.* , 1974; Chu *et al.* , 1975; Meera Khan *et al.* , 1978; Westerveld

et al. , 1978; Benn *et al.* , 1979; Mohandas *et al.* , 1979). The GALT genes (*GAL7*) from two yeast

species (*Saccharomyces cerevisiae* and *Kluyveromyces lactis*) were among the first to be sequenced,

providing useful information to enable to the search for homologues in other species (Citron & Donelson , 1984; Riley & Dickson , 1984). The coding sequence of the human gene was determined in 1988 (Reichardt & Berg , 1988) and the first disease-associated mutations identified in 1991 (Reichardt & Woo , 1991). Genomic sequencing revealed that human *GALT* is arranged into 11 exons (Leslie *et al.* , 1992). A mutation which changes glutamine 188 to arginine (p.Q188R) was shown to be the most common cause of galactosemia in Caucasians (Reichardt *et al.* , 1991; Leslie *et al.* , 1992). This mutation accounts for 63-90% of cases of type I galactosemia in this ethnic group (Suzuki *et al.* , 2001; Coss *et al.* , 2013). In African populations (and groups descended therefrom) the p.S135L variant is the most common (Lai *et al.* , 1996). The *GALT* gene's location on chromosome 9 was finally confirmed by the human genome project (Lander *et al.* , 2001; Venter *et al.* , 2001). There are now over 200 disease-associated mutations in the *GALT* gene (Calderon *et al.* , 2007; d'Acierno *et al.* , 2009). Of these, the vast majority of these result in single amino acid changes. Two databases of these mutations have been created. One focuses on documenting disease-associated mutations (www.arup.utah.edu/database/galt/galt_welcome.php (Calderon *et al.* , 2007)) and the other on the effects of these mutations on GALT's structure and function (http://bioinformatica.isa.cnr.it/galactosemia-proteins-db/index3.html (d'Acierno *et al.* , 2009; d'Acierno *et al.* , 2014)).

Two more types of galactosemia: types II and III

The belief that all cases of galactosemia resulted from dysfunction of GALT was challenged by the discovery, in 1967, of two children with cataracts and high blood galactose concentrations (Gitzelmann , 1967). Clinical chemistry investigations demonstrated that GALT activity was normal and extracts from blood cells were able to metabolise galactose 1-phosphate. However, galactokinase activity was not detectable (Gitzelmann , 1967). Therefore, galactokinase deficiency must also result in a form of galactosemia. Further cases were reported in the following years, some

7

being detected through large-scale screening programmes (Thalhammer *et al.* , 1968; Olambiwonnu *et al.* , 1974). Like type I galactosemia, heterozygotes were largely asymptomatic except for reduced blood enzyme activity (Mayes & Guthrie , 1968; Pickering & Howell , 1972).

The galactokinase gene was located to chromosome 17 (S. Elsevier *et al.* , 1974; Orkwiszewski *et al.* , 1974; S. M. Elsevier *et al.* , 1975). Cloning and sequencing of the gene was complicated by the unexpected existence of a second galactokinase-like sequence in the human genome, *GALK2*. This gene encodes the structurally and functionally related protein N-acetylgalactosamine kinase (EC 2.7.1.157), an enzyme which has only minimal activity towards galactose (Lee *et al.* , 1992; Ai *et al.* , 1995; Thoden & Holden , 2005; Agnew & Timson , 2010). The coding sequence for *GALK2* was determined three years before that the *GALK1* was elucidated in 1995 (Stambolian *et al.* , 1995). This study also identified two disease-associated mutations (Stambolian *et al.* , 1995). The genomic sequence of *GALK1* showed that the gene spans eight exons on chromosome 17 (Bergsma *et al.* , 1996). Approximately 40 disease-associated mutations in *GALK1* are now known (Holden *et al.* , 2004; Timson *et al.* , 2009).

In 1981, Holton and coworkers reported the case of a child who had similar symptoms to patients with classical galactosemia, but with normal GALT activity and diminished GALE activity (Holton *et al.* , 1981). It was noted that treatment of this third form of galactosemia by dietary galactose restriction might be particularly problematic. In unaffected individuals, UDP-galactose (a key precursor in glycoprotein and glycolipid synthesis) can be synthesised either from galactose through part of the Leloir pathway or from glucose which is converted to UDP-glucose and then epimerised to UDP-galactose by GALE. In type III galactosemia the second route is not available and a balance needs to be made between restricting galactose intake and providing enough for the synthesis of UDP-galactose (Holton *et al.* , 1981). Interestingly, Holton was not the first to describe a case of reduced GALE activity. Almost a decade before, Gitzelmann described the case of a patient with

reduced GALE activity but no symptoms of galactosemia (Gitzelmann , 1972; Gitzelmann *et al.* , 1977).

Further patients with type III galactosemia were identified and the disease was classified clinically into two forms – an essentially benign peripheral form and a severe, generalised form (Garibaldi *et al.* , 1983; Henderson *et al.* , 1983; Sardharwalla *et al.* , 1988; W. G. Ng *et al.* , 1993; Walter *et al.* , 1999). In the case of the peripheral form, the only manifestation was altered levels of galactose and some metabolites in the blood and no intervention was normally recommended. The division between the two forms was challenged by the identification of a number of mutations associated with an "intermediate" form of the disease (Openo *et al.* , 2006). Of the three types of galactosemia, type III has the smallest number (~25) of identified disease-associated mutations (Timson , 2006; T. J. McCorvie & Timson , 2013; T. J. McCorvie & Timson , 2014). However, these mutations result in a range of severity of symptoms demonstrating that rather than being a binary (or tertiary) condition, type III galactosemia results in a range of outcomes from the almost benign to life-threatening (Openo *et al.* , 2006).

The human *GALE* gene was mapped to chromosome 1 (Benn Shows *et al.* , 1979; Lin *et al.* , 1979). The coding sequence was determined in 1995 (Daude *et al.* , 1995). Genomic DNA sequencing showed that the gene is organised into 11 exons and five mutations associated with type III galactosemia were identified (Maceratesi *et al.* , 1998). The most common mutation associated with a severe form of the disease, which codes for p.V94M, was discovered in 1999 (Wohlers *et al.* , 1999). In addition to its role in the Leloir pathway, human GALE also catalyses the interconversion of N-acetylgalactosamine and N-acetylglucoasamine (Piller *et al.* , 1983; Schulz *et al.* , 2004). This reaction is important in maintaining the pools of UDP-sugars used in the synthesis of glycoproteins and glycolipids and loss of this activity may explain the abnormal glycosylation patterns seen in some cell culture and animal models of type III galactosemia (Kingsley *et al.* , 1986; Rosoff , 1995; Brokate-Llanos *et al.* , 2014).

The present: modern molecular methods applied to galactosemia

The discovery of the coding sequences for *GALT*, *GALK1* and *GALE* opened the door to the application of molecular biology studies. Of particular note, it enabled determination of protein structures, detailed biochemical studies using recombinant proteins and the use of "model organisms" to study the disease. To date, the structure of human GALT has not been reported. The structure of the enzyme from *Escherichia coli* was the first to be determined (Wedekind *et al.* , 1995; Wedekind *et al.* , 1996; Thoden *et al.* , 1997). This structure has been used to develop homology models of the human enzyme and all known disease-associated variants (Marabotti & Facchiano , 2005; Facchiano & Marabotti , 2010; d'Acierno *et al.* , 2014). The structure of human GALK1 was solved in 2005 and that of human GALE in 2000 (Thoden *et al.* , 2000; Thoden Wohlers Fridovich-Keil Holden , 2001a; Thoden *et al.* , 2005). In addition to the wild-type structure of GALE, the disease-associated variant p.V94M has also been solved (Thoden Wohlers Fridovich-Keil Holden , 2001b). This is the only variant associated with any type of galactosemia for which an experimental structure is currently known.

All three of the enzymes have been subjected to detailed biochemical studies. Disease-associated variants of GALT tend to have lower enzymatic activity and some are less able to dimerise when compared to the wild-type (Wells & Fridovich-Keil , 1997; Lai *et al.* , 1999; T. J. McCorvie *et al.* , 2013). Underlying these defects is a failure of the variant enzymes to fold correctly (T. J. McCorvie *et al.* , 2013). Misfolding is often accompanied by aggregation of the disease-associated variants (Coelho *et al.* , 2014). In the case of galactokinase, defects in enzymatic activity approximately correlate with disease severity (Timson & Reece , 2003a; Sangiuolo *et al.* , 2004). To date, no detailed studies on the effects of disease-associated variants on the folding of the enzyme have been completed. The story is similar for GALE: disease-associated variants tend to have lower activity than the wild-type and this reduction in activity is generally greater in variants associated with

10

severe forms of the disease (Wohlers & Fridovich-Keil , 2000; Timson , 2005). Some disease-associated variants aggregate when expressed in cultured mammalian cells (Bang *et al.* , 2009). The loss of activity often results from a failure to fold correctly and, in some cases, reduced affinity for the catalytically vital NAD$^+$ cofactor (Quimby *et al.* , 1997; T. J. McCorvie *et al.* , 2012).

Although studies on isolated enzymes have been useful for understanding the fundamental, molecular basis of the disease, it is also necessary to understand the effects on cells, organs and whole organisms. Over the years, the budding yeast *S. cerevisiae* has proved to be a useful model system for studying both type I and type III galactosemia (Wells & Fridovich-Keil , 1996). This organism is well-suited to the task since it does not require galactose to grow and reproduce. Therefore, strains which lack the genes encoding GALT or GALE (or which carry disease-associated mutations) will be unaffected while growing in glucose. However, if the yeast are switched into media in which galactose is the main carbon source then they may exhibit a phenotype depending on the allele(s) present. The human *GALT* and *GALE* genes are able to complement their yeast orthologues (*GAL7* and *GAL10* respectively) (Fridovich-Keil *et al.* , 1995; Quimby *et al.* , 1997). *S. cerevisiae* has been used a variety of studies on the cellular effects of human *GALT* and *GALE* mutations including the effects of various mutations on cellular metabolite concentrations (for examples see (Riehman *et al.* , 2001; Mumma *et al.* , 2008)). Since heterodimers can form in a heterozygous yeast strain expressing both wild-type and variant GALT, the system is also useful for investigating the effects of heterozygosity. For heterodimers of wild-type and either p.Q188R or p.R333W enzymatic activity was reduced to around 14% and 45% respectively of the wild-type homodimer level (J. P. Elsevier & Fridovich-Keil , 1996; J. P. Elsevier *et al.* , 1996). Homodimers of either p.Q188R or p.R333W had essentially no detectable activity under the same assay conditions (J. P. Elsevier *et al.* , 1996). Heterodimers were also less stable to thermal denaturation than wild-type homodimers (J. P. Elsevier & Fridovich-Keil , 1996). These data suggest that these alleles may be partially dominant notwithstanding the observation that in patients' families heterozygotes normally do not present with the disease, and that the degree of dominance varies with the

11

mutations present (J. P. Elsevier & Fridovich-Keil , 1996). Similar results were seen with GALE

heterodimers expressed in yeast cells. While a wild-type/p.V94M heterodimer had approximately

50% activity (compared to a wild-type homodimer), heterodimers of the wild-type with either

p.N34S or p.L183P showed less than 50% activity (Quimby *et al.* , 1997; Wohlers *et al.* , 1999).

Homodimers of p.V94M or p.L183P had no detectable activity under similar assay conditions,

whereas homodimers of p.N34S had approximately 70% of wild-type activity (Quimby *et al.* , 1997;

Wohlers *et al.* , 1999). One intriguing result from yeast is that the endogenous GALT and GALE

proteins (Gal10p and Gal7p) colocalise in the cytoplasm indicating that the Leloir pathway enzymes

may form a complex (or metabolon) (Christacos *et al.* , 2000). When human *GALT* is substituted for

GAL7, the GALT protein also colocalises with Gal10p suggesting that metabolon formation is

conserved from yeast to humans (Christacos *et al.* , 2000). The consequences of this for galactose

metabolism *in vivo* or how it has is affected by disease-associated mutations has not yet been

investigated.

Despite its many advantages, *S. cerevisiae* is ultimately limited as a model organism for

understanding galactosemia since it is unicellular. In recent years a number of important

multicellular models have been developed and have been used to generate interesting results. A

mouse model for type I galactosemia was generated in 1996. Although the model recapitulated

many of the biochemical phenotypes of galactosemia, acute galactose toxicity and consequent

pathology were not observed (Leslie *et al.* , 1996; Ning *et al.* , 2000; Ning *et al.* , 2001). The reasons

for this were unclear. However, it has been suggested that upregulation of human tumour

suppressor gene aplysia ras homolog I (*ARHI*) in response to the metabolic disturbances associated

with galactosemia may be implicated (Lai *et al.* , 2008). The ARHI protein causes increased apoptosis

and reduced growth; the gene is not present in rodents potentially explaining the lack of effect in

this mouse model (Yu *et al.* , 1999; Bao *et al.* , 2002; Fitzgerald & Bateman , 2004). In the last twelve

months a second mouse model for GALT deficiency has been reported. In this case, pathology was

observed with the majority of *galt*-null pups fed by mothers on a high galactose diet dying before

12

weaning (Tang *et al.* , 2014). These pups also showed altered ratios of oxidised:reduced glutathione, consistent with increased oxidative stress and adult females showed reduced numbers of ovarian follicles (Tang *et al.* , 2014). The difference in results between these two studies most likely results from the early feeding of pups with high concentrations of galactose. Increased oxidative stress was also observed in a *Drosophila melanogaster* model of type I galactosemia (Kushner *et al.* , 2010; P. P. Jumbo-Lucioni *et al.* , 2013). This model also showed defects in the nervous system with consequent impacts on locomotion of the flies (Ryan *et al.* , 2012; P. Jumbo-Lucioni *et al.* , 2014).

A mouse model for type II galactosemia in which the *galk1* gene was disrupted showed no phenotype. However, when the mice were further modified so that they expressed aldose reductase they developed cataracts (Ai *et al.* , 2000). A key difference between mice and humans is that mice have much lower expression of aldose reductase in the lens cells of the eye. This enzyme catalyses the conversion of galactose to its corresponding sugar alcohol galactitol (dulcitol) and it is this compound which appears to be responsible for the damaging osmotic influx of water into the lens cells (Hayman & Kinoshita , 1965; Dvornik *et al.* , 1973; Ai *et al.* , 2000). Reactive oxygen species are also implicated in the formation of galactosemic cataracts (Mulhern *et al.* , 2006; Mulhern *et al.* , 2007; Abdul Nasir *et al.* , 2014). *D. melanogaster* and *Caenorhabditis elegans* models of type III galactosemia have also been developed (Sanders *et al.* , 2010; Brokate-Llanos *et al.* , 2014). The fruit fly model demonstrated that GALE is essential for development of the organism (Sanders *et al.* , 2010). It also demonstrated that the two physiologically important activities of GALE (epimerisation of UDP-galactose and UDP-N-acetylgalactosamine) were vital and played different roles in development (Daenzer *et al.* , 2012). Developmental defects were also been observed in the *C. elegans* model (Brokate-Llanos *et al.* , 2014).

It is becoming increasingly apparent that disruption of normal glycosylation of proteins and lipids is also a feature of the pathology of type I and type III galactosemia. Defects in the glycosylation of neuronal cells from a galactosemic patient was first noted in the early 1970s (Haberland *et al.* ,

1971). Reduced levels of galactosylation of proteins from cells and serum derived from patients with type I galactosemia has been observed in several studies (Dobbie *et al.* , 1990; Ornstein *et al.* , 1992; Stibler *et al.* , 1997; Charlwood *et al.* , 1998; Coss *et al.* , 2014). It was hypothesised that this is caused by the reduced levels of UDP-galactose often observed in cells derived from galactosemia patients (W. G. Ng *et al.* , 1989). In addition to decreased galactosylation, increased inappropriate incorporation of other monosaccharide moieties such as fucose has been observed (Sturiale *et al.* , 2005). Similarly, glycolipids from galactosemic patients were shown to have reduced levels of galactose and N-acetylgalactosamine compared to healthy patients; this effect was not reversed by a low galactose diet (Petry *et al.* , 1991). In galactosemic patients, N-linked protein glycosylation is associated with increased amounts of mannose and increased numbers of truncated oligosaccharide chains (Y. Liu *et al.* , 2012; Staubach *et al.* , 2012). O-linked glycosylation of proteins is also affected with increased numbers of shorter oligosaccharides (Y. Liu *et al.* , 2012). Recently, it has been suggested that N-glycosylation patterns could be a valuable biomarker for monitoring the severity of the disease and the effectiveness of treatment regimes (Coss *et al.* , 2012; Coss *et al.* , 2014; Knerr *et al.* , 2015).

The future: a realistic chance for therapy?

Recent biochemical work suggests a number of strategies for improved therapy for galactosemia. It is believed that galactose 1-phosphate build-up in types I and III contributes to toxicity. Therefore, blocking the activity of galactokinase which would prevent the accumulation of this compound may be beneficial (Bosch *et al.* , 2002). The availability of a high resolution structure of GALK1 has enabled structure-based drug design and the discovery of some high affinity specific inhibitors of the enzyme (Wierenga *et al.* , 2008; Tang *et al.* , 2010; Odejinmi *et al.* , 2011; Chiappori *et al.* , 2013; Lai *et al.* , 2014; L. Liu *et al.* , 2015). The observation that GALT deficiency is accompanied by increased oxidative stress suggests that antioxidants may be beneficial. A manganese containing porphyrin

14

compound which mimics the activity of superoxide dismutase has been shown to be effective in the fruit fly model (P. P. Jumbo-Lucioni Ryan *et al.* , 2013). The use of dietary antioxidants has also been suggested (Timson , 2014). Since protein misfolding is likely to be the fundamental cause of most cases of galactosemia, it may be possible to discover molecules which stabilise and promote proper folding of the variant proteins thus increasing enzymatic activity and reducing the tendency to aggregate. Such "pharmacological chaperones" have the potential to restore enzyme activity and alleviate or prevent the bulk of the symptoms (Ringe & Petsko , 2009; Muntau *et al.* , 2014; Brandvold & Morimoto , 2015). This approach has identified compounds which are being used in the successful treatment of cystic fibrosis and transthyretin amyloidoses (Sampson *et al.* , 2011; Bulawa *et al.* , 2012; Hanrahan *et al.* , 2013). Similar approaches are also being developed for a range of other inherited metabolic diseases including Fabry disease, Pompe disease, methylmalonic aciduria, hyperoxaluria, and phenylketonuria (J. J. Flanagan *et al.* , 2009; Pey *et al.* , 2011; Santos-Sierra *et al.* , 2012; Underhaug *et al.* , 2012; Cammisa *et al.* , 2013; Jorge-Finnigan *et al.* , 2013; Mesa-Torres *et al.* , 2013). Discovering pharmacological chaperones for galactosemia will be challenging; however, the existence of good quality experimental structures or models of the three enzymes together with robust assays for their stability will assist the process. Recently, it has been shown that arginine stabilises GALT, including the variant forms p.Q188R and p.K285N supporting the concept that small molecules can enhance the stability and activity of this protein (Coelho *et al.* , 2015). Since misfolded proteins are likely to be targeted for proteosomal degradation, thus further reducing cellular activity, an alternative approach is to inhibit these degradation processes using proteostasis modulators. These can increase the cellular half-lives of misfolded proteins (Vij , 2011). In a mouse model, proteasome inhibitors were able to partially correct cystathionine β-synthase deficiency (Gupta *et al.* , 2013).

Thus after over a century of scientific progress in the understanding of galactosemia, we are finally poised to put this knowledge into practice and develop better treatments for this inherited metabolic disease. It is unlikely that any one of the treatment strategies outlined above will provide

15

an adequate therapy for all patients with galactosemia. The existence of three types of the disease and the wide range of disease-associated mutations combined with environmental variability, results in considerable diversity of disease phenotypes. There is also a need to treat altered metabolite levels, disturbed glycosylation patterns and the increase in free radical concentrations. Therefore, combinations of treatment approaches and careful monitoring of patients using a variety of biomarkers is likely to be required. In all cases, dietary restriction of galactose will probably continue to be needed. However, the next 100 years should see impressive advances in the treatment of galactosemic patients and there is potential for therapies to be developed which enable near-normal quality of life for these people.

Acknowledgments

References

Abdul Nasir, N. A., Agarwal, R., Vasudevan, S., Tripathy, M., Alyautdin, R., & Ismail, N. M., 2014. Effects of topically applied tocotrienol on cataractogenesis and lens redox status in galactosemic rats. Mol.Vis. 20, 822-835.

Adam, S., Akroyd, R., Bernabei, S., Bollhalder, S., Boocock, S., Burlina, A., Coote, T., Corthouts, K., Dalmau, J., Dawson, S., Defourny, S., De Meyer, A., Desloovere, A., Devlin, Y., Diels, M., Dokoupil, K., Donald, S., Evans, S., Fasan, I., Ferguson, C., Ford, S., Forga, M., Gallo, G., Grunert, S. C., Heddrich-Ellerbrok, M., Heidenborg, C., Jonkers, C., Lefebure, K., Luyten, K., MacDonald, A., Meyer, U., Micciche, A., Muller, E., Portnoi, P., Ripley, S., Robert, M., Robertson, L. V., Rosenbaum-Fabian, S., Sahm, K., Schultz, S., Singleton, K., Sjoqvist, E., Stoelen, L., Terry, A., Thompson, S., Timmer, C., Vande Kerckhove, K., van der Ploeg, L., Van Driessche, M., van Rijn, M., van Teeffelen-Heithoff, A., Vitoria, I., Voillot, C., Wenz, J., Westbrook, M., Wildgoose, J., & Zweers, H., 2015. How strict is galactose restriction in adults with galactosaemia? International practice. Mol.Genet.Metab. 115, 23-26.

Agnew, A., & Timson, D., 2010. Mechanistic studies on human N-acetylgalactosamine kinase. J.Enzyme Inhib.Med.Chem. 25, 370-376.

Ai, Y., Basu, M., Bergsma, D. J., & Stambolian, D., 1995. Comparison of the enzymatic activities of human galactokinase GALK1 and a related human galactokinase protein GK2. Biochem.Biophys.Res.Commun. 212, 687-691.

Ai, Y., Zheng, Z., O'Brien-Jenkins, A., Bernard, D. J., Wynshaw-Boris, T., Ning, C., Reynolds, R., Segal, S., Huang, K., & Stambolian, D., 2000. A mouse model of galactose-induced cataracts. Hum.Mol.Genet. 9, 1821-1827.

Bailey, J. M., Fishman, P. H., & Pentchev, P. G., 1969. Studies on mutarotases. 3. Isolation and characterization of a mutarotase from bovine kidney cortex. J.Biol.Chem. 244, 781-788.

Bang, Y. L., Nguyen, T. T., Trinh, T. T., Kim, Y. J., Song, J., & Song, Y. H., 2009. Functional analysis of mutations in UDP-galactose-4-epimerase (GALE) associated with galactosemia in Korean patients using mammalian GALE-null cells. FEBS J. 276, 1952-1961.

Bao, J. J., Le, X. F., Wang, R. Y., Yuan, J., Wang, L., Atkinson, E. N., LaPushin, R., Andreeff, M., Fang, B., Yu, Y., & Bast, R. C.,Jr, 2002. Reexpression of the tumor suppressor gene *ARHI* induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res. 62, 7264-7272.

Bell, L. S., Blair, W. C., Lindsay, S., & Watson, S. J., 1950. Galactose diabetes (galactosemia): A clinicopathologic study of two siblings. J.Pediatr. 36, 427-439.

Benn, P. A., D'Ancona, G. G., Croce, C. M., Shows, T. B., & Mellman, W. J., 1979. Confirmation of the assignment of the gene for galactose-1-phosphate uridylyltransferase (E.C. 2.7.7.12) to human chromosome 9. Cytogenet.Cell Genet. 24, 37-41.

Benn, P. A., Shows, T. B., D'Ancona, G. G., Croce, C. M., Orkwiszewski, K. G., & Mellman, W. J., 1979. Assignment of a gene for uridine diphosphate galactose-4-epimerase to human chromosome 1 by somatic cell hybridization, with evidence for a regional assignment to 1pter yields 1p21. Cytogenet.Cell Genet. 24, 138-142.

Bergsma, D. J., Ai, Y., Skach, W. R., Nesburn, K., Anoia, E., Van Horn, S., & Stambolian, D., 1996. Fine structure of the human galactokinase *GALK1* gene. Genome Res. 6, 980-985.

Berry, G. T., 2012. Galactosemia: when is it a newborn screening emergency?. Mol.Genet.Metab. 106, 7-11.

Bosch, A. M., 2006. Classical galactosaemia revisited. J.Inherit.Metab.Dis. 29, 516-525.

Bosch, A. M., Bakker, H. D., van Gennip, A. H., van Kempen, J. V., Wanders, R. J., & Wijburg, F. A., 2002. Clinical features of galactokinase deficiency: a review of the literature. J.Inherit.Metab.Dis. 25, 629-634.

Brandvold, K. R., & Morimoto, R. I., 2015. The Chemical Biology of Molecular Chaperones-Implications for Modulation of Proteostasis. J.Mol.Biol. In press.

Brokate-Llanos, A. M., Monje, J. M., Murdoch Pdel, S., & Munoz, M. J., 2014. Developmental defects in a *Caenorhabditis elegans* model for type III galactosemia. Genetics. 198, 1559-1569.

Bruck, E., & Rapoport, S., 1945. Galactosemia in an infant with cataracts: clinical observations and carbohydrate studies. American Journal of Diseases of Children. 70, 267-276.

Bulawa, C. E., Connelly, S., Devit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J., Powers, E. T., Wiseman, R. L., Foss, T. R., Wilson, I. A., Kelly, J. W., & Labaudiniere, R., 2012. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc.Natl.Acad.Sci.U.S.A. 109, 9629-9634.

Cabib, E., 1970. Research on sugar nucleotides brings honor to Argentinian biochemist (Luis Leloir). Science. 170, 608-609.

Calderon, F. R., Phansalkar, A. R., Crockett, D. K., Miller, M., & Mao, R., 2007. Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene. Hum.Mutat. 28, 939-943.

Cammisa, M., Correra, A., Andreotti, G., & Cubellis, M. V., 2013. Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones. Orphanet J.Rare Dis. 8, 111-1172-8-111.

Caputto, R., Leloir, L. F., Cardini, C. E., & Paladini, A. C., 1950. Isolation of the coenzyme of the galactose phosphate-glucose phosphate transformation. J Biol Chem. 184, 333-350.

Caputto, R., Leloir, L. F., Trucco, R. E., Cardini, C. E., & Paladini, A. C., 1949. The enzymatic transformation of galactose into glucose derivatives. J. Biol. Chem. 179, 497-498.

Cardini, C., Paladini, A., Caputto, R., & Leloir, L., 1950. Uridine diphosphate glucose: the coenzyme of the galactose-glucose phosphate isomerization. Nature. 165, 191-192.

Charlwood, J., Clayton, P., Keir, G., Mian, N., & Winchester, B., 1998. Defective galactosylation of serum transferrin in galactosemia. Glycobiology. 8, 351-357.

Chiappori, F., Merelli, I., Milanesi, L., & Marabotti, A., 2013. Static and dynamic interactions between GALK enzyme and known inhibitors: guidelines to design new drugs for galactosemic patients. Eur.J.Med.Chem. 63, 423-434.

Christacos, N. C., Marson, M. J., Wells, L., Riehman, K., & Fridovich-Keil, J. L., 2000. Subcellular localization of galactose-1-phosphate uridylyltransferase in the yeast *Saccharomyces cerevisiae*. Mol.Genet.Metab. 70, 272-280.

Chu, E. H., Chang, C. C., & Sun, N. C., 1975. Synteny of the human genes for Gal-1-PT, ACP1, MDH-1, and Gal+-Act and assignment to chromosome 2. Birth Defects Orig.Artic.Ser. 11, 103-106.

Citron, B. A., & Donelson, J. E., 1984. Sequence of the *Saccharomyces GAL* region and its transcription *in vivo*. J.Bacteriol. 158, 269-278.

Coelho, A. I., Trabuco, M., Ramos, R., Silva, M. J., Tavares de Almeida, I., Leandro, P., Rivera, I., & Vicente, J. B., 2014. Functional and structural impact of the most prevalent missense mutations in classic galactosemia. Mol.Genet.Genomic Med. 2, 484-496.

Coelho, A. I., Trabuco, M., Silva, M. J., de Almeida, I. T., Leandro, P., Rivera, I., & Vicente, J. B., 2015. Arginine Functionally Improves Clinically Relevant Human Galactose-1-Phosphate Uridylyltransferase (GALT) Variants Expressed in a Prokaryotic Model. JIMD Rep. In press.

Coss, K. P., Byrne, J. C., Coman, D. J., Adamczyk, B., Abrahams, J. L., Saldova, R., Brown, A. Y., Walsh, O., Hendroff, U., Carolan, C., Rudd, P. M., & Treacy, E. P., 2012. IgG N-glycans as potential

biomarkers for determining galactose tolerance in Classical Galactosaemia. Mol.Genet.Metab. 105, 212-220.

Coss, K. P., Doran, P. P., Owoeye, C., Codd, M. B., Hamid, N., Mayne, P. D., Crushell, E., Knerr, I., Monavari, A. A., & Treacy, E. P., 2013. Classical Galactosaemia in Ireland: incidence, complications and outcomes of treatment. J.Inherit.Metab.Dis. 36, 21-27.

Coss, K. P., Hawkes, C. P., Adamczyk, B., Stockmann, H., Crushell, E., Saldova, R., Knerr, I., Rubio-Gozalbo, M. E., Monavari, A. A., Rudd, P. M., & Treacy, E. P., 2014. N-glycan abnormalities in children with galactosemia. J.Proteome Res. 13, 385-394.

d'Acierno, A., Facchiano, A., & Marabotti, A., 2014. GALT protein database: querying structural and functional features of GALT enzyme. Hum.Mutat. 35, 1060-1067.

d'Acierno, A., Facchiano, A., & Marabotti, A., 2009. GALT protein database, a bioinformatics resource for the management and analysis of structural features of a galactosemia-related protein and its mutants. Genomics Proteomics Bioinformatics. 7, 71-76.

Daenzer, J. M., Sanders, R. D., Hang, D., & Fridovich-Keil, J. L., 2012. UDP-galactose 4'-epimerase activities toward UDP-Gal and UDP-GalNAc play different roles in the development of *Drosophila melanogaster*. PLoS Genet. 8, e1002721.

Daude, N., Gallaher, T. K., Zeschnigk, M., Starzinski-Powitz, A., Petry, K. G., Haworth, I. S., & Reichardt, J. K., 1995. Molecular cloning, characterization, and mapping of a full-length cDNA encoding human UDP-galactose 4'-epimerase. Biochem.Mol.Med. 56, 1-7.

Dobbie, J. A., Holton, J. B., & Clamp, J. R., 1990. Defective galactosylation of proteins in cultured skin fibroblasts from galactosaemic patients. Ann.Clin.Biochem. 27 (Pt 3), 274-275.

Donnell, G. N., Bergren, W. R., Perry, G., & Koch, R., 1963. Galactose-1-phosphate in galactosemia. Pediatrics. 31, 802-810.

Dvornik, E., Simard-Duquesne, N., Krami, M., Sestanj, K., Gabbay, K. H., Kinoshita, J. H., Varma, S. D., & Merola, L. O., 1973. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science. 182, 1146-1148.

Elsevier, S., Kucherlapati, R., Nichols, E., Creagan, R., Giles, R., Ruddle, F., Willecke, K., & McDougall, J., 1974. Assignment of the gene for galactokinase to human chromosome 17 and its regional localisation to band q21-22.

Elsevier, J. P., & Fridovich-Keil, J. L., 1996. The Q188R mutation in human galactose-1-phosphate uridylyltransferase acts as a partial dominant negative. J.Biol.Chem. 271, 32002-32007.

Elsevier, J. P., Wells, L., Quimby, B. B., & Fridovich-Keil, J. L., 1996. Heterodimer formation and activity in the human enzyme galactose-1-phosphate uridylyltransferase. Proc.Natl.Acad.Sci.U.S.A. 93, 7166-7171.

Elsevier, S. M., Kucherlapati, R. S., Nichols, E. A., Willecke, K., Creagan, R. P., Giles, R. E., McDougall, J. K., & Ruddle, F. H., 1975. Assigment and regional localization of a gene coding for galactokinase to human chromosome 17q21-22. Cytogenet.Cell Genet. 14, 287-289.

Facchiano, A., & Marabotti, A., 2010. Analysis of galactosemia-linked mutations of GALT enzyme using a computational biology approach. Protein Eng.Des.Sel. 23, 103-113.

Fitzgerald, J., & Bateman, J. F., 2004. Why mice have lost genes for *COL21A1*, *STK17A*, *GPR145* and *AHRI*: evidence for gene deletion at evolutionary breakpoints in the rodent lineage. Trends Genet. 20, 408-412.

Flanagan, J. J., Rossi, B., Tang, K., Wu, X., Mascioli, K., Donaudy, F., Tuzzi, M. R., Fontana, F., Cubellis, M. V., Porto, C., Benjamin, E., Lockhart, D. J., Valenzano, K. J., Andria, G., Parenti, G., & Do, H. V., 2009. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid α-glucosidase. Hum.Mutat. 30, 1683-1692.

Flanagan, J. M., McMahon, G., Brendan Chia, S. H., Fitzpatrick, P., Tighe, O., O'Neill, C., Briones, P., Gort, L., Kozak, L., Magee, A., Naughten, E., Radomyska, B., Schwartz, M., Shin, J. S., Strobl, W. M., Tyfield, L. A., Waterham, H. R., Russell, H., Bertorelle, G., Reichardt, J. K., Mayne, P. D., & Croke, D. T., 2010. The role of human demographic history in determining the distribution and frequency of transferase-deficient galactosaemia mutations. Heredity. 104, 148-154.

Frey, P. A., 1996. The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. FASEB J. 10, 461-470.

Fridovich-Keil, J. L., 2006. Galactosemia: the good, the bad, and the unknown. J.Cell.Physiol. 209, 701-705.

Fridovich-Keil, J. L., Gubbels, C. S., Spencer, J. B., Sanders, R. D., Land, J. A., & Rubio-Gozalbo, E., 2011. Ovarian function in girls and women with GALT-deficiency galactosemia. J.Inherit.Metab.Dis. 34, 357-366.

Fridovich-Keil, J. L., Langley, S. D., Mazur, L. A., Lennon, J. C., Dembure, P. P., & Elsas, J. L.,2nd, 1995. Identification and functional analysis of three distinct mutations in the human galactose-1-phosphate uridyltransferase gene associated with galactosemia in a single family. Am.J.Hum.Genet. 56, 640-646.

Fridovich-Keil, J. L., Walter, J. H., 2008. Galactosemia, in: Valle, D., Beaudet, A. L., Vogelstein, B., Kinzler, K. W., Antonarakis, S. E., Ballabio, A. (Eds.), The Online Metabolic and Molecular Bases of Inherited Diseases. McGraw-Hill, New York.

Garibaldi, L. R., Canini, S., Superti-Furga, A., Lamedica, G., Filocamo, M., Marchese, N., & Borrone, C., 1983. Galactosemia caused by generalized uridine diphosphate galactose-4-epimerase deficiency. J.Pediatr. 103, 927-930.

23

Gitzelmann, R., 1972. Deficiency of uridine diphosphate galactose 4-epimerase in blood cells of an apparently healthy infant. Preliminary communication. Helv.Paediatr.Acta. 27, 125-130.

Gitzelmann, R., 1967. Hereditary Galactokinase Deficiency, a Newly Recognized Cause of Juvenile Cataracts. Pediatr.Res. 1, 14-23.

Gitzelmann, R., & Steinmann, B., 1984. Galactosemia: how does long-term treatment change the outcome?. Enzyme. 32, 37-46.

Gitzelmann, R., Steinmann, B., Mitchell, B., & Haigis, E., 1977. Uridine diphosphate galactose 4'-epimerase deficiency. IV. Report of eight cases in three families. Helv.Paediatr.Acta. 31, 441-452.

Gleason, L., Rasberry, M., & van Calcar, S., 2000. Understanding Galactosemia - A Diet Guide, 2nd ed. Biochemical Genetics Program, University of Wisconsin-Madison, Madison.

Goeppert-Mayer, M., 1963. The shell model. Nobel Lectures: Physics. 3.

Goldbloom, A., & Brickman, H. F., 1946. Galactemia. J.Pediatr. 28, 674-691.

Göppert, F., 1917. Galaktosurie nach Milchzuckergabe bei angeborenem, familiaerem chronischem Leberleiden. Klin Wschr. 54, 473-477.

Greenman, L., & Rathbun, J. C., 1948. Galactose studies in an infant with idiopathic galactose intolerance. Pediatrics. 2, 666-672.

Gupta, S., Wang, L., Anderl, J., Slifker, M. J., Kirk, C., & Kruger, W. D., 2013. Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors. Hum.Mutat. 34, 1085-1093.

Haberland, C., Perou, M., Brunngraber, E. G., & Hof, H., 1971. The neuropathology of galactosemia. A histopathological and biochemical study. J.Neuropathol.Exp.Neurol. 30, 431-447.

Hanrahan, J. W., Sampson, H. M., & Thomas, D. Y., 2013. Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol.Sci. 34, 119-125.

Hayman, S., & Kinoshita, J. H., 1965. Isolation and properties of lens aldose reductase. J.Biol.Chem. 240, 877-882.

Henderson, M. J., Holton, J. B., & MacFaul, R., 1983. Further observations in a case of uridine diphosphate galactose-4-epimerase deficiency with a severe clinical presentation. J.Inherit.Metab.Dis. 6, 17-20.

Hennermann, J. B., Schadewaldt, P., Vetter, B., Shin, Y. S., Monch, E., & Klein, J., 2011. Features and outcome of galactokinase deficiency in children diagnosed by newborn screening. J.Inherit.Metab.Dis. 34, 399-407.

Holden, H. M., Thoden, J. B., Timson, D. J., & Reece, R. J., 2004. Galactokinase: structure, function and role in type II galactosemia. Cell Mol.Life Sci. 61, 2471-2484.

Holton, J. B., 1996. Galactosaemia: pathogenesis and treatment. J.Inherit.Metab.Dis. 19, 3-7.

Holton, J. B., Gillett, M. G., MacFaul, R., & Young, R., 1981. Galactosaemia: a new severe variant due to uridine diphosphate galactose-4-epimerase deficiency. Arch.Dis.Child. 56, 885-887.

Hsia, D. Y., Huang, I., & Driscoll, S. G., 1958. The heterozygous carrier in galactosaemia. Nature. 182, 1389-1390.

Hugh-Jones, K., Newcomb, A. L., & Hsia, D. Y., 1960. The genetic mechanism of galactosaemia. Arch.Dis.Child. 35, 521-528.

Isselbacher, K. J., Anderson, E. P., Kurahashi, K., & Kalckar, H. M., 1956. Congenital galactosemia, a single enzymatic block in galactose metabolism. Science. 123, 635-636.

Janzen, N., Illsinger, S., Meyer, U., Shin, Y. S., Sander, J., Lucke, T., & Das, A. M., 2011. Early cataract formation due to galactokinase deficiency: impact of newborn screening. Arch.Med.Res. 42, 608-612.

Jorge-Finnigan, A., Brasil, S., Underhaug, J., Ruiz-Sala, P., Merinero, B., Banerjee, R., Desviat, L. R., Ugarte, M., Martinez, A., & Perez, B., 2013. Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type. Hum.Mol.Genet. 22, 3680-3689.

Jumbo-Lucioni, P., Parkinson, W., & Broadie, K., 2014. Overelaborated synaptic architecture and reduced synaptomatrix glycosylation in a *Drosophila* classic galactosemia disease model. Dis.Model.Mech. 7, 1365-1378.

Jumbo-Lucioni, P. P., Hopson, M. L., Hang, D., Liang, Y., Jones, D. P., & Fridovich-Keil, J. L., 2013. Oxidative stress contributes to outcome severity in a *Drosophila melanogaster* model of classic galactosemia. Dis.Model.Mech. 6, 84-94.

Jumbo-Lucioni, P. P., Ryan, E. L., Hopson, M., Bishop, H., Weitner, T., Tovmasyan, A., Spasojevic, I., Batinic-Haberle, I., Liang, Y., Jones, D. P., & Fridovich-Keil, J. L., 2013. Manganese-based superoxide dismutase mimics modify both acute and long-term outcome severity in a *Drosophila melanogaster* model of classic galactosemia. Antioxid.Redox Signal. In press.

Kalckar, H. M., Anderson, E. P., & Isselbacher, K. J., 1956a. Galactosemia, a congenital defect in a nucleotide transferase. Biochim.Biophys.Acta. 20, 262-268.

Kalckar, H. M., Anderson, E. P., & Isselbacher, K. J., 1956b. Galactosemia, a Congenital Defect in a Nucleotide Transferase: a Preliminary Report. Proc.Natl.Acad.Sci.U.S.A. 42, 49-51.

Karadag, N., Zenciroglu, A., Eminoglu, F. T., Dilli, D., Karagol, B. S., Kundak, A., Dursun, A., Hakan, N., & Okumus, N., 2013. Literature review and outcome of classic galactosemia diagnosed in the neonatal period. Clin.Lab. 59, 1139-1146.

Kingsley, D. M., Kozarsky, K. F., Hobbie, L., & Krieger, M., 1986. Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell. 44, 749-759.

Knerr, I., Coss, K. P., Kratzsch, J., Crushell, E., Clark, A., Doran, P., Shin, Y., Stockmann, H., Rudd, P. M., & Treacy, E., 2015. Effects of temporary low-dose galactose supplements in children aged 5-12 years with Classical Galactosaemia: a pilot study. Pediatr.Res.

Kushner, R. F., Ryan, E. L., Sefton, J. M., Sanders, R. D., Lucioni, P. J., Moberg, K. H., & Fridovich-Keil, J. L., 2010. A *Drosophila melanogaster* model of classic galactosemia. Dis.Model.Mech. 3, 618-627.

Lai, K., Boxer, M. B., & Marabotti, A., 2014. GALK inhibitors for classic galactosemia. Future Med.Chem. 6, 1003-1015.

Lai, K., Langley, S. D., Singh, R. H., Dembure, P. P., Hjelm, L. N., & Elsas, L. J.,2nd, 1996. A prevalent mutation for galactosemia among black Americans. J.Pediatr. 128, 89-95.

Lai, K., Tang, M., Yin, X., Klapper, H., Wierenga, K., & Elsas, L., 2008. ARHI: A new target of galactose toxicity in Classic Galactosemia. Biosci.Hypotheses. 1, 263-271.

Lai, K., Willis, A. C., & Elsas, L. J., 1999. The biochemical role of glutamine 188 in human galactose-1-phosphate uridyltransferase. J.Biol.Chem. 274, 6559-6566.

Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., McKernan, K., Meldrim, J., Mesirov, J. P., Miranda, C., Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos, R., Sheridan, A., Sougnez, C., Stange-Thomann, N., Stojanovic, N., Subramanian, A., Wyman, D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I., Durbin, R., French, L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C.,

McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J. C., Mungall, A., Plumb, R., Ross, M., Shownkeen, R., Sims, S., Waterston, R. H., Wilson, R. K., Hillier, L. W., McPherson, J. D., Marra, M. A., Mardis, E. R., Fulton, L. A., Chinwalla, A. T., Pepin, K. H., Gish, W. R., Chissoe, S. L., Wendl, M. C., Delehaunty, K. D., Miner, T. L., Delehaunty, A., Kramer, J. B., Cook, L. L., Fulton, R. S., Johnson, D. L., Minx, P. J., Clifton, S. W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P., Wenning, S., Slezak, T., Doggett, N., Cheng, J. F., Olsen, A., Lucas, S., Elkin, C., Uberbacher, E., Frazier, M., Gibbs, R. A., Muzny, D. M., Scherer, S. E., Bouck, J. B., Sodergren, E. J., Worley, K. C., Rives, C. M., Gorrell, J. H., Metzker, M. L., Naylor, S. L., Kucherlapati, R. S., Nelson, D. L., Weinstock, G. M., Sakaki, Y., Fujiyama, A., Hattori, M., Yada, T., Toyoda, A., Itoh, T., Kawagoe, C., Watanabe, H., Totoki, Y., Taylor, T., Weissenbach, J., Heilig, R., Saurin, W., Artiguenave, F., Brottier, P., Bruls, T., Pelletier, E., Robert, C., Wincker, P., Smith, D. R., Doucette-Stamm, L., Rubenfield, M., Weinstock, K., Lee, H. M., Dubois, J., Rosenthal, A., Platzer, M., Nyakatura, G., Taudien, S., Rump, A., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., Hood, L., Rowen, L., Madan, A., Qin, S., Davis, R. W., Federspiel, N. A., Abola, A. P., Proctor, M. J., Myers, R. M., Schmutz, J., Dickson, M., Grimwood, J., Cox, D. R., Olson, M. V., Kaul, R., Raymond, C., Shimizu, N., Kawasaki, K., Minoshima, S., Evans, G. A., Athanasiou, M., Schultz, R., Roe, B. A., Chen, F., Pan, H., Ramser, J., Lehrach, H., Reinhardt, R., McCombie, W. R., de la Bastide, M., Dedhia, N., Blocker, H., Hornischer, K., Nordsiek, G., Agarwala, R., Aravind, L., Bailey, J. A., Bateman, A., Batzoglou, S., Birney, E., Bork, P., Brown, D. G., Burge, C. B., Cerutti, L., Chen, H. C., Church, D., Clamp, M., Copley, R. R., Doerks, T., Eddy, S. R., Eichler, E. E., Furey, T. S., Galagan, J., Gilbert, J. G., Harmon, C., Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K., Jang, W., Johnson, L. S., Jones, T. A., Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W. J., Kitts, P., Koonin, E. V., Korf, I., Kulp, D., Lancet, D., Lowe, T. M., McLysaght, A., Mikkelsen, T., Moran, J. V., Mulder, N., Pollara, V. J., Ponting, C. P., Schuler, G., Schultz, J., Slater, G., Smit, A. F., Stupka, E., Szustakowski, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L., Wallis, J., Wheeler, R., Williams, A., Wolf, Y. I., Wolfe, K. H., Yang, S. P., Yeh, R. F., Collins, F., Guyer, M. S., Peterson, J., Felsenfeld, A., Wetterstrand, K. A., Patrinos, A., Morgan, M. J., de Jong, P., Catanese, J. J., Osoegawa, K., Shizuya, H., Choi, S., Chen, Y. J., & International Human

Genome Sequencing Consortium, 2001. Initial sequencing and analysis of the human genome. Nature. 409, 860-921.

Lee, R. T., Peterson, C. L., Calman, A. F., Herskowitz, I., & O'Donnell, J. J., 1992. Cloning of a human galactokinase gene (GK2) on chromosome 15 by complementation in yeast. Proc.Natl.Acad.Sci.U.S.A. 89, 10887-10891.

Leloir, L. F., 1983. Far away and long ago. Annu.Rev.Biochem. 52, 1-16.

Leloir, L. F., 1951. The enzymatic transformation of uridine diphosphate glucose into a galactose derivative. Arch.Biochem. 33, 186-190.

Leslie, N. D., Immerman, E. B., Flach, J. E., Florez, M., Fridovich-Keil, J. L., & Elsas, L. J., 1992. The human galactose-1-phosphate uridyltransferase gene. Genomics. 14, 474-480.

Leslie, N. D., Yager, K. L., McNamara, P. D., & Segal, S., 1996. A mouse model of galactose-1-phosphate uridyl transferase deficiency. Biochem.Mol.Med. 59, 7-12.

Lin, M. S., Oizumi, J., Ng, W. G., Alfi, O. S., & Donnell, G. N., 1979. Regional mapping of the gene for human UDPGal 4-epimerase on chromosome 1 in mouse-human hybrids. Cytogenet.Cell Genet. 24, 217-223.

Liu, L., Tang, M., Walsh, M. J., Brimacombe, K. R., Pragani, R., Tanega, C., Rohde, J. M., Baker, H. L., Fernandez, E., Blackman, B., Bougie, J. M., Leister, W. H., Auld, D. S., Shen, M., Lai, K., & Boxer, M. B., 2015. Structure activity relationships of human galactokinase inhibitors. Bioorg.Med.Chem.Lett. 25, 721-727.

Liu, Y., Xia, B., Gleason, T. J., Castaneda, U., He, M., Berry, G. T., & Fridovich-Keil, J. L., 2012. N- and O-linked glycosylation of total plasma glycoproteins in galactosemia. Mol.Genet.Metab. 106, 442-454.

Maceratesi, P., Daude, N., Dallapiccola, B., Novelli, G., Allen, R., Okano, Y., & Reichardt, J., 1998. Human UDP-galactose 4' epimerase (GALE) gene and identification of five missense mutations in patients with epimerase-deficiency galactosemia. Mol.Genet.Metab. 63, 26-30.

Marabotti, A., & Facchiano, A. M., 2005. Homology modeling studies on human galactose-1-phosphate uridylyltransferase and on its galactosemia-related mutant Q188R provide an explanation of molecular effects of the mutation on homo- and heterodimers. J.Med.Chem. 48, 773-779.

Mason, H. H., & Turner, M. E., 1935. Chronic galactemia: report of case with studies on carbohydrates. American Journal of Diseases of Children. 50, 359-374.

Maxwell, E. S., 1956. Diphosphopyridine nucleotide, a cofactor for galacto-waldenase. J.Am.Chem.Soc. 78, 1074-1074.

Mayes, J. S., & Guthrie, R., 1968. Detection of heterozygotes for galactokinase deficiency in a human population. Biochem.Genet. 2, 219-230.

McCorvie, T. J., Gleason, T. J., Fridovich-Keil, J. L., & Timson, D. J., 2013. Misfolding of galactose 1-phosphate uridylyltransferase can result in type I galactosemia. Biochim.Biophys.Acta. 1832, 1279-1293.

McCorvie, T. J., Liu, Y., Frazer, A., Gleason, T. J., Fridovich-Keil, J. L., & Timson, D. J., 2012. Altered cofactor binding affects stability and activity of human UDP-galactose 4'-epimerase: implications for type III galactosemia. Biochim.Biophys.Acta. 1822, 1516-1526.

McCorvie, T. J., & Timson, D. J., 2013. *In silico* prediction of the effects of mutations in the human UDP-galactose 4'-epimerase gene: Towards a predictive framework for type III galactosemia. Gene. 524, 95-104.

McCorvie, T. J., & Timson, D. J., 2011a. Structural and molecular biology of type I galactosemia: disease-associated mutations. IUBMB Life. 63, 949-954.

McCorvie, T. J., & Timson, D. J., 2011b. The structural and molecular biology of type I galactosemia: Enzymology of galactose 1-phosphate uridylyltransferase. IUBMB Life. 63, 694-700.

McCorvie, T. J., Timson, D. J., 2014. UDP-galactose 4-epimerase (GALE), in: Taniguchi, N., Honke, K., Fukuda, M., Narimatsu, H., Yamaguchi, Y., Angata, T. (Eds.), Handbook of Glycosyltransferases and Related Genes, 2nd ed. Springer, New York, pp. Chapter 133.

Meera Khan, P., Wijnen, L. M., & Pearson, P. L., 1978. Assignment of a human galactose-1-phosphate uridylyltransferase gene (GALT1) to chromosome 9 in human-Chinese hamster somatic cell hybrids. Cytogenet.Cell Genet. 22, 207-211.

Mellinkoff, S., Roth, B., & MacLaggan, J., 1945. Galactosemia with hepatic damage: Report of a case in an infant with recovery. J.Pediatr. 27, 338-342.

Mesa-Torres, N., Fabelo-Rosa, I., Riverol, D., Yunta, C., Albert, A., Salido, E., & Pey, A. L., 2013. The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I. PLoS One. 8, e71963.

Mohandas, T., Sparkes, R. S., Sparkes, M. C., Shulkin, J. D., Toomey, K. E., & Funderburk, S. J., 1979. Regional localization of human gene loci on chromosome 9: studies of somatic cell hybrids containing human translocations. Am.J.Hum.Genet. 31, 586-600.

Mulhern, M. L., Madson, C. J., Danford, A., Ikesugi, K., Kador, P. F., & Shinohara, T., 2006. The unfolded protein response in lens epithelial cells from galactosemic rat lenses. Invest.Ophthalmol.Vis.Sci. 47, 3951-3959.

Mulhern, M. L., Madson, C. J., Kador, P. F., Randazzo, J., & Shinohara, T., 2007. Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Mol.Vis. 13, 1397-1405.

Mumma, J. O., Chhay, J. S., Ross, K. L., Eaton, J. S., Newell-Litwa, K. A., & Fridovich-Keil, J. L., 2008. Distinct roles of galactose-1P in galactose-mediated growth arrest of yeast deficient in galactose-1P uridylyltransferase (GALT) and UDP-galactose 4'-epimerase (GALE). Mol.Genet.Metab. 93, 160-171.

Muntau, A. C., Leandro, J., Staudigl, M., Mayer, F., & Gersting, S. W., 2014. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J.Inherit.Metab.Dis. 37, 505-523.

Murphy, M., McHugh, B., Tighe, O., Mayne, P., O'Neill, C., Naughten, E., & Croke, D. T., 1999. Genetic basis of transferase-deficient galactosaemia in Ireland and the population history of the Irish Travellers. Eur.J.Hum.Genet. 7, 549-554.

Ng, W. G., Bergren, W., & Donnell, G., 1964. Galactose-1-phosphate uridyltransferase assay by use of radioactive galactose-1-phosphate. Clinica Chimica Acta. 10, 337-343.

Ng, W. G., Xu, Y., Cowan, T. M., Blitzer, M. G., Allen, R. J., Bock, H. O., Kruckeberg, W. C., & Levy, H. L., 1993. Erythrocyte uridine diphosphate galactose-4-epimerase deficiency identified by newborn screening for galactosemia in the United States. Screening. 2, 179-186.

Ng, W. G., Xu, Y. K., Kaufman, F. R., & Donnell, G. N., 1989. Deficit of uridine diphosphate galactose in galactosaemia. J.Inherit.Metab.Dis. 12, 257-266.

Ning, C., Reynolds, R., Chen, J., Yager, C., Berry, G. T., Leslie, N., & Segal, S., 2001. Galactose metabolism in mice with galactose-1-phosphate uridyltransferase deficiency: sucklings and 7-week-old animals fed a high-galactose diet. Mol.Genet.Metab. 72, 306-315.

Ning, C., Reynolds, R., Chen, J., Yager, C., Berry, G. T., McNamara, P. D., Leslie, N., & Segal, S., 2000. Galactose metabolism by the mouse with galactose-1-phosphate uridyltransferase deficiency. Pediatr.Res. 48, 211-217.

Odejinmi, S., Rascon, R., Tang, M., Vankayalapati, H., & Lai, K., 2011. Structure-activity analysis and cell-based optimization of human galactokinase inhibitors. ACS Med.Chem.Lett. 2, 667-672.

Olambiwonnu, N. O., McVie, R., Ng, W. G., Frasier, S. D., & Donnell, G. N., 1974. Galactokinase deficiency in twins: clinical and biochemical studies. Pediatrics. 53, 314-318.

Openo, K. K., Schulz, J. M., Vargas, C. A., Orton, C. S., Epstein, M. P., Schnur, R. E., Scaglia, F., Berry, G. T., Gottesman, G. S., Ficicioglu, C., Slonim, A. E., Schroer, R. J., Yu, C., Rangel, V. E., Keenan, J., Lamance, K., & Fridovich-Keil, J. L., 2006. Epimerase-deficiency galactosemia is not a binary condition. Am.J.Hum.Genet. 78, 89-102.

Orkwiszewski, K. G., Tedesco, T. A., & Croce, C. M., 1974. Assignment of the human gene for galactokinase to chromosome 17. Nature. 252, 60-62.

Ornstein, K. S., McGuire, E. J., Berry, G. T., Roth, S., & Segal, S., 1992. Abnormal galactosylation of complex carbohydrates in cultured fibroblasts from patients with galactose-1-phosphate uridyltransferase deficiency. Pediatr.Res. 31, 508-511.

Paladini, A. C., & Leloir, L. F., 1952. Studies on uridine-diphosphate-glucose. Biochem.J. 51, 426-430.

Petry, K., Greinix, H. T., Nudelman, E., Eisen, H., Hakomori, S., Levy, H. L., & Reichardt, J. K., 1991. Characterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes. Biochem.Med.Metab.Biol. 46, 93-104.

Pey, A. L., Salido, E., & Sanchez-Ruiz, J. M., 2011. Role of low native state kinetic stability and interaction of partially unfolded states with molecular chaperones in the mitochondrial protein mistargeting associated with primary hyperoxaluria. Amino Acids. 41, 1233-1245.

Pickering, W. R., & Howell, R. R., 1972. Galactokinase deficiency: clinical and biochemical findings in a new kindred. J.Pediatr. 81, 50-55.

Piller, F., Hanlon, M. H., & Hill, R. L., 1983. Co-purification and characterization of UDP-glucose 4-epimerase and UDP-N-acetylglucosamine 4-epimerase from porcine submaxillary glands. J.Biol.Chem. 258, 10774-10778.

Potter, N. L., Nievergelt, Y., & Shriberg, L. D., 2013. Motor and speech disorders in classic galactosemia. JIMD Rep. 11, 31-41.

Quimby, B. B., Alano, A., Almashanu, S., DeSandro, A. M., Cowan, T. M., & Fridovich-Keil, J. L., 1997. Characterization of two mutations associated with epimerase-deficiency galactosemia, by use of a yeast expression system for human UDP-galactose-4-epimerase. Am.J.Hum.Genet. 61, 590-598.

Reichardt, J. K., & Berg, P., 1988. Cloning and characterization of a cDNA encoding human galactose-1-phosphate uridyl transferase. Mol.Biol.Med. 5, 107-122.

Reichardt, J. K., Packman, S., & Woo, S. L., 1991. Molecular characterization of two galactosemia mutations: correlation of mutations with highly conserved domains in galactose-1-phosphate uridyl transferase. Am.J.Hum.Genet. 49, 860-867.

Reichardt, J. K., & Woo, S. L., 1991. Molecular basis of galactosemia: mutations and polymorphisms in the gene encoding human galactose-1-phosphate uridylyltransferase. Proc.Natl.Acad.Sci.U.S.A. 88, 2633-2637.

Reiner, J. M., 1947. Metabolic Intermediates in Adaptive Fermentation of Galactose by Yeast. J.Gen.Physiol. 30, 355-365.

Ridel, K. R., Leslie, N. D., & Gilbert, D. L., 2005. An updated review of the long-term neurological effects of galactosemia. Pediatr.Neurol. 33, 153-161.

Riehman, K., Crews, C., & Fridovich-Keil, J. L., 2001. Relationship between genotype, activity, and galactose sensitivity in yeast expressing patient alleles of human galactose-1-phosphate uridylyltransferase. J.Biol.Chem. 276, 10634-10640.

Riley, M. I., & Dickson, R. C., 1984. Genetic and biochemical characterization of the galactose gene cluster in *Kluyveromyces lactis*. J.Bacteriol. 158, 705-712.

Ringe, D., & Petsko, G. A., 2009. What are pharmacological chaperones and why are they interesting?. J.Biol. 8, 80.

Rosoff, P. M., 1995. Myelodysplasia and deficiency of uridine diphosphate-galactose 4-epimerase. J.Pediatr. 127, 605-608.

Rubio-Gozalbo, M. E., Gubbels, C. S., Bakker, J. A., Menheere, P. P., Wodzig, W. K., & Land, J. A., 2010. Gonadal function in male and female patients with classic galactosemia. Hum.Reprod.Update. 16, 177-188.

Ryan, E. L., DuBoff, B., Feany, M. B., & Fridovich-Keil, J. L., 2012. Mediators of a long-term movement abnormality in a Drosophila melanogaster model of classic galactosemia. Dis.Model.Mech. 5, 796-803.

Sampson, H. M., Robert, R., Liao, J., Matthes, E., Carlile, G. W., Hanrahan, J. W., & Thomas, D. Y., 2011. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem.Biol. 18, 231-242.

Sanders, R. D., Sefton, J. M., Moberg, K. H., & Fridovich-Keil, J. L., 2010. UDP-galactose 4' epimerase (GALE) is essential for development of *Drosophila melanogaster*. Dis.Model.Mech. 3, 628-638.

Sangiuolo, F., Magnani, M., Stambolian, D., & Novelli, G., 2004. Biochemical characterization of two GALK1 mutations in patients with galactokinase deficiency. Hum.Mutat. 23, 396.

Santos-Sierra, S., Kirchmair, J., Perna, A. M., Reiss, D., Kemter, K., Roschinger, W., Glossmann, H., Gersting, S. W., Muntau, A. C., Wolber, G., & Lagler, F. B., 2012. Novel pharmacological chaperones that correct phenylketonuria in mice. Hum.Mol.Genet. 21, 1877-1887.

Sardharwalla, I., Wraith, J., Bridge, C., Fowler, B., Roberts, S., 1988. A patient with severe type of epimerase deficiency galactosaemia, in: Anonymous Studies in Inherited Metabolic Disease. Springer, pp. 249-251.

Schulz, J. M., Watson, A. L., Sanders, R., Ross, K. L., Thoden, J. B., Holden, H. M., & Fridovich-Keil, J. L., 2004. Determinants of function and substrate specificity in human UDP-galactose 4'-epimerase. J.Biol.Chem. 279, 32796-32803.

Schweitzer, S., Shin, Y., Jakobs, C., & Brodehl, J., 1993. Long-term outcome in 134 patients with galactosaemia. Eur.J.Pediatr. 152, 36-43.

Shahani, K. M., & Chandan, R. C., 1979. Nutritional and healthful aspects of cultured and culture-containing dairy foods. J.Dairy Sci. 62, 1685-1694.

Spratt, N. T., 1949. Nutritional requirements of the early chick embryo. I. The utilization of carbohydrate substrates. J.Exp.Zool. 110, 273-298.

Stambolian, D., Ai, Y., Sidjanin, D., Nesburn, K., Sathe, G., Rosenberg, M., & Bergsma, D. J., 1995. Cloning of the galactokinase cDNA and identification of mutations in two families with cataracts. Nat.Genet. 10, 307-312.

Staubach, S., Schadewaldt, P., Wendel, U., Nohroudi, K., & Hanisch, F. G., 2012. Differential glycomics of epithelial membrane glycoproteins from urinary exovesicles reveals shifts toward complex-type N-glycosylation in classical galactosemia. J.Proteome Res. 11, 906-916.

Stibler, H., von Dobeln, U., Kristiansson, B., & Guthenberg, C., 1997. Carbohydrate-deficient transferrin in galactosaemia. Acta Paediatr. 86, 1377-1378.

Sturiale, L., Barone, R., Fiumara, A., Perez, M., Zaffanello, M., Sorge, G., Pavone, L., Tortorelli, S., O'Brien, J. F., Jaeken, J., & Garozzo, D., 2005. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. Glycobiology. 15, 1268-1276.

Suzuki, M., West, C., & Beutler, E., 2001. Large-scale molecular screening for galactosemia alleles in a pan-ethnic population. Hum.Genet. 109, 210-215.

Tang, M., Siddiqi, A., Witt, B., Yuzyuk, T., Johnson, B., Fraser, N., Chen, W., Rascon, R., Yin, X., Goli, H., Bodamer, O. A., & Lai, K., 2014. Subfertility and growth restriction in a new galactose-1 phosphate uridylyltransferase (GALT) - deficient mouse model. Eur.J.Hum.Genet. 22, 1172-1179.

Tang, M., Wierenga, K., Elsas, L. J., & Lai, K., 2010. Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem.Biol.Interact. 188, 376-385.

Tedesco, T. A., Diamond, R., Orkwiszewski, K. G., Boedecker, H. J., & Croce, C. M., 1974. Assignment of the human gene for hexose-1-phosphate uridylyltransferase to chromosome 3. Proc.Natl.Acad.Sci.U.S.A. 71, 3483-3486.

Thalhammer, O., Gitzelmann, R., & Pantlitschko, M., 1968. Hypergalactosemia and galactosuria due to galactokinase deficiency in a newborn. Pediatrics. 42, 441-445.

Thoden, J. B., & Holden, H. M., 2005. The molecular architecture of human N-acetylgalactosamine kinase. J.Biol.Chem. 280, 32784-32791.

Thoden, J. B., Ruzicka, F. J., Frey, P. A., Rayment, I., & Holden, H. M., 1997. Structural analysis of the H166G site-directed mutant of galactose-1-phosphate uridylyltransferase complexed with either UDP-glucose or UDP-galactose: detailed description of the nucleotide sugar binding site. Biochemistry. 36, 1212-1222.

Thoden, J. B., Timson, D. J., Reece, R. J., & Holden, H. M., 2005. Molecular structure of human galactokinase: implications for type II galactosemia. J.Biol.Chem. 280, 9662-9670.

Thoden, J. B., Timson, D. J., Reece, R. J., & Holden, H. M., 2004. Molecular structure of human galactose mutarotase. J.Biol.Chem. 279, 23431-23437.

Thoden, J. B., Wohlers, T. M., Fridovich-Keil, J. L., & Holden, H. M., 2001a. Human UDP-galactose 4-epimerase. Accommodation of UDP-N-acetylglucosamine within the active site. J.Biol.Chem. 276, 15131-15136.

Thoden, J. B., Wohlers, T. M., Fridovich-Keil, J. L., & Holden, H. M., 2001b. Molecular basis for severe epimerase deficiency galactosemia. X-ray structure of the human V94m-substituted UDP-galactose 4-epimerase. J.Biol.Chem. 276, 20617-20623.

Thoden, J. B., Wohlers, T. M., Fridovich-Keil, J. L., & Holden, H. M., 2000. Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose 4-epimerase. Biochemistry. 39, 5691-5701.

Timmers, I., van den Hurk, J., Di Salle, F., Rubio-Gozalbo, M. E., & Jansma, B. M., 2011. Language production and working memory in classic galactosemia from a cognitive neuroscience perspective: future research directions. J.Inherit.Metab.Dis. 34, 367-376.

Timmers, I., Zhang, H., Bastiani, M., Jansma, B. M., Roebroeck, A., & Rubio-Gozalbo, M. E., 2015. White matter microstructure pathology in classic galactosemia revealed by neurite orientation dispersion and density imaging. J.Inherit.Metab.Dis. 38, 295-304.

Timson, D. J., 2014. Purple sweet potato colour - a potential therapy for galactosemia?. Int.J.Food Sci.Nutr. 65, 391-393.

Timson, D. J., 2006. The structural and molecular biology of type III galactosemia. IUBMB Life. 58, 83-89.

Timson, D. J., 2005. Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase. FEBS J. 272, 6170-6177.

Timson, D. J., & Reece, R. J., 2003a. Functional analysis of disease-causing mutations in human galactokinase. Eur.J.Biochem. 270, 1767-1774.

Timson, D. J., & Reece, R. J., 2003b. Identification and characterisation of human aldose 1-epimerase. FEBS Lett. 543, 21-24.

Timson, D. J., Reece, R. J., Thoden, J. B., Holden, H. M., 2009. Galactokinase Deficiency, in: Lang, F. (Ed.), Encyclopedia of Molecular Mechanisms of Disease. Springer, Berlin and Heidelberg, pp. 679-680.

Trucco, R. E., Caputto, R., Leloir, L. F., & Mittleman, N., 1948. Galactokinase. Arch.Biochem. 18, 137-146.

Tyfield, L., Reichardt, J., Fridovich-Keil, J., Croke, D. T., Elsas, L. J.,2nd, Strobl, W., Kozak, L., Coskun, T., Novelli, G., Okano, Y., Zekanowski, C., Shin, Y., & Boleda, M. D., 1999. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum.Mutat. 13, 417-430.

Underhaug, J., Aubi, O., & Martinez, A., 2012. Phenylalanine hydroxylase misfolding and pharmacological chaperones. Curr.Top.Med.Chem. 12, 2534-2545.

Van Calcar, S. C., Bernstein, L. E., Rohr, F. J., Scaman, C. H., Yannicelli, S., & Berry, G. T., 2014. A re-evaluation of life-long severe galactose restriction for the nutrition management of classic galactosemia. Mol.Genet.Metab. 112, 191-197.

Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., Gocayne, J. D., Amanatides, P., Ballew, R. M., Huson, D. H., Wortman, J. R., Zhang, Q., Kodira, C. D., Zheng, X. H., Chen, L., Skupski, M., Subramanian, G., Thomas, P. D., Zhang, J., Gabor Miklos, G. L., Nelson, C., Broder, S., Clark, A. G., Nadeau, J., McKusick, V. A., Zinder, N., Levine, A. J., Roberts, R. J., Simon, M., Slayman, C., Hunkapiller, M., Bolanos, R., Delcher, A., Dew, I., Fasulo, D., Flanigan, M., Florea, L., Halpern, A., Hannenhalli, S., Kravitz, S., Levy, S., Mobarry, C., Reinert, K., Remington, K., Abu-Threideh, J., Beasley, E., Biddick, K., Bonazzi, V., Brandon, R., Cargill, M., Chandramouliswaran, I., Charlab, R., Chaturvedi, K., Deng, Z., Di Francesco, V., Dunn, P., Eilbeck, K., Evangelista, C., Gabrielian, A. E., Gan, W., Ge, W., Gong, F., Gu, Z., Guan, P., Heiman, T. J., Higgins,

M. E., Ji, R. R., Ke, Z., Ketchum, K. A., Lai, Z., Lei, Y., Li, Z., Li, J., Liang, Y., Lin, X., Lu, F., Merkulov, G. V., Milshina, N., Moore, H. M., Naik, A. K., Narayan, V. A., Neelam, B., Nusskern, D., Rusch, D. B., Salzberg, S., Shao, W., Shue, B., Sun, J., Wang, Z., Wang, A., Wang, X., Wang, J., Wei, M., Wides, R., Xiao, C., Yan, C., Yao, A., Ye, J., Zhan, M., Zhang, W., Zhang, H., Zhao, Q., Zheng, L., Zhong, F., Zhong, W., Zhu, S., Zhao, S., Gilbert, D., Baumhueter, S., Spier, G., Carter, C., Cravchik, A., Woodage, T., Ali, F., An, H., Awe, A., Baldwin, D., Baden, H., Barnstead, M., Barrow, I., Beeson, K., Busam, D., Carver, A., Center, A., Cheng, M. L., Curry, L., Danaher, S., Davenport, L., Desilets, R., Dietz, S., Dodson, K., Doup, L., Ferriera, S., Garg, N., Gluecksmann, A., Hart, B., Haynes, J., Haynes, C., Heiner, C., Hladun, S., Hostin, D., Houck, J., Howland, T., Ibegwam, C., Johnson, J., Kalush, F., Kline, L., Koduru, S., Love, A., Mann, F., May, D., McCawley, S., McIntosh, T., McMullen, I., Moy, M., Moy, L., Murphy, B., Nelson, K., Pfannkoch, C., Pratts, E., Puri, V., Qureshi, H., Reardon, M., Rodriguez, R., Rogers, Y. H., Romblad, D., Ruhfel, B., Scott, R., Sitter, C., Smallwood, M., Stewart, E., Strong, R., Suh, E., Thomas, R., Tint, N. N., Tse, S., Vech, C., Wang, G., Wetter, J., Williams, S., Williams, M., Windsor, S., Winn-Deen, E., Wolfe, K., Zaveri, J., Zaveri, K., Abril, J. F., Guigo, R., Campbell, M. J., Sjolander, K. V., Karlak, B., Kejariwal, A., Mi, H., Lazareva, B., Hatton, T., Narechania, A., Diemer, K., Muruganujan, A., Guo, N., Sato, S., Bafna, V., Istrail, S., Lippert, R., Schwartz, R., Walenz, B., Yooseph, S., Allen, D., Basu, A., Baxendale, J., Blick, L., Caminha, M., Carnes-Stine, J., Caulk, P., Chiang, Y. H., Coyne, M., Dahlke, C., Mays, A., Dombroski, M., Donnelly, M., Ely, D., Esparham, S., Fosler, C., Gire, H., Glanowski, S., Glasser, K., Glodek, A., Gorokhov, M., Graham, K., Gropman, B., Harris, M., Heil, J., Henderson, S., Hoover, J., Jennings, D., Jordan, C., Jordan, J., Kasha, J., Kagan, L., Kraft, C., Levitsky, A., Lewis, M., Liu, X., Lopez, J., Ma, D., Majoros, W., McDaniel, J., Murphy, S., Newman, M., Nguyen, T., Nguyen, N., Nodell, M., Pan, S., Peck, J., Peterson, M., Rowe, W., Sanders, R., Scott, J., Simpson, M., Smith, T., Sprague, A., Stockwell, T., Turner, R., Venter, E., Wang, M., Wen, M., Wu, D., Wu, M., Xia, A., Zandieh, A., & Zhu, X., 2001. The sequence of the human genome. Science. 291, 1304-1351.

Vij, N., 2011. The case for therapeutic proteostasis modulators. Expert Opin.Ther.Targets. 15, 233-236.

Von Reuss, A., 1908. Zuckerausscheidung im Säuglingsalter. Wien.Med.Wochenschr. 58, 799-801.

Waggoner, D. D., Buist, N. R., & Donnell, G. N., 1990. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J.Inherit.Metab.Dis. 13, 802-818.

Waisbren, S. E., Potter, N. L., Gordon, C. M., Green, R. C., Greenstein, P., Gubbels, C. S., Rubio-Gozalbo, E., Schomer, D., Welt, C., Anastasoaie, V., D'Anna, K., Gentile, J., Guo, C. Y., Hecht, L., Jackson, R., Jansma, B. M., Li, Y., Lip, V., Miller, D. T., Murray, M., Power, L., Quinn, N., Rohr, F., Shen, Y., Skinder-Meredith, A., Timmers, I., Tunick, R., Wessel, A., Wu, B. L., Levy, H., Elsas, L., & Berry, G. T., 2012. The adult galactosemic phenotype. J.Inherit.Metab.Dis. 35, 279-286.

Walter, J. H., Roberts, R. E., Besley, G. T., Wraith, J. E., Cleary, M. A., Holton, J. B., & MacFaul, R., 1999. Generalised uridine diphosphate galactose-4-epimerase deficiency. Arch.Dis.Child. 80, 374-376.

Wedekind, J. E., Frey, P. A., & Rayment, I., 1996. The structure of nucleotidylated histidine-166 of galactose-1-phosphate uridylyltransferase provides insight into phosphoryl group transfer. Biochemistry. 35, 11560-11569.

Wedekind, J. E., Frey, P. A., & Rayment, I., 1995. Three-dimensional structure of galactose-1-phosphate uridylyltransferase from Escherichia coli at 1.8 A resolution. Biochemistry. 34, 11049-11061.

Wells, L., & Fridovich-Keil, J. L., 1997. Biochemical characterization of the S135L allele of galactose-1-phosphate uridylyltransferase associated with galactosaemia. J.Inherit.Metab.Dis. 20, 633-642.

Wells, L., & Fridovich-Keil, J. L., 1996. The yeast, *Saccharomyces cerevisiae*, as a model system for the study of human genetic disease. SAAS Bull.Biochem.Biotechnol. 9, 83-88.

Westerveld, A., Garver, J., Nijman, M. A., & Pearson, P. L., 1978. Regional localization of the genes

coding for human red cell adenylate kinase, aconitase, and galactose-1-phosphate

uridylyltransferase on chromosome 9. Cytogenet.Cell Genet. 22, 465-467.

Widhalm, K., Miranda da Cruz, B. D., & Koch, M., 1997. Diet does not ensure normal development in

galactosemia. J.Am.Coll.Nutr. 16, 204-208.

Wierenga, K. J., Lai, K., Buchwald, P., & Tang, M., 2008. High-throughput screening for human

galactokinase inhibitors. J.Biomol.Screen. 13, 415-423.

Wilkinson, J. F., 1949. The pathway of adaptive fermentation in yeast. Biochem. J. 44, 460-467.

Wohlers, T. M., Christacos, N. C., Harreman, M. T., & Fridovich-Keil, J. L., 1999. Identification and

characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with

generalized epimerase-deficiency galactosemia. Am.J.Hum.Genet. 64, 462-470.

Wohlers, T. M., & Fridovich-Keil, J. L., 2000. Studies of the V94M-substituted human UDPgalactose-4-

epimerase enzyme associated with generalized epimerase-deficiency galactosaemia.

J.Inherit.Metab.Dis. 23, 713-729.

Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W. L., Gray, J. W., Siciliano, M., Mills,

G. B., & Bast, R. C.,Jr, 1999. *NOEY2* (*ARHI*), an imprinted putative tumor suppressor gene in ovarian

and breast carcinomas. Proc.Natl.Acad.Sci.U.S.A. 96, 214-219.

Figure legends

<u>Figure 1:</u> The Leloir pathway of galactose catabolism. In this pathway, α-D-galactose is first phosphorylated at the expense of ATP in a reaction catalysed by galactokinase (GALK1). Impairment of this reaction can result in type II galactosemia. α-D-Galactose 1-phosphate then reacts with UDP-glucose, forming glucose 1-phosphate and UDP-galactose. This reaction is catalysed by galactose 1-phosphate uridylyltransferase (GALT) and deficiency of this enzyme can cause type I galactosemia. The glucose 1-phosphate produced in this reaction can be isomerised to glucose 6-phosphate by phosphoglucomutase and thus enter glycolysis. The reversal of stereochemistry occurs when UDP-galactose is recycled to UDP-glucose in a reaction catalysed by UDP-galactose 4'-epimerase (GALE). Mutations in the gene coding for this enzyme can lead to type III galactosemia. This enzyme also catalyses the interconversion of UDP-*N*-acetylgalactosamine and UDP-*N*-acetyglucosamine. Both reactions are important in maintaining the cellular pools of UDP-sugars for use in the synthesis of glycolipids and glycoproteins.

Figure 1

α-D-galactose

Type II
galactosemia   GALK1

MgATP

MgADP

α-D-galactose-1-phosphate

Type I
galactosemia   GALT

UDP-Glucose

UDP-Galactose

GALE   *Type III*
galactosemia

α-D-glucose-1-phosphate

44

Graphical abstract

Galactosemia – past, present and future

Abbreviations list

GALK1: Galctokianse

GALK2: N-acetylgalactosamine kinase

GALT: Galactose 1-phosphate uridylyltransferase

GALE: UDP-galactose 4'-epimerase

PGM: Phosphoglucomutase

GALM: Galactose mutarotase

DPN: Diphosphopyridine nucleotide (former name for NAD^+)

The molecular basis of galactosemia: past, present and future

Highlights

- Galactosemia was first described in 1908 by von Ruess
- Leloir discovered the pathway of galactose catabolism
- Kalckar determined that GALT deficiency is the cause of classic galactosemia
- Two other forms exist: GALK1 and GALE deficiency
- Modern molecular approaches are suggesting ways to improve treatment